METHODOLOGY OF MONITORED RELEASE OF A NEW PREPARATION - BUPRENORPHINE

被引：20

作者：

HARCUS, AW ^{[1
]}

WARD, AE ^{[1
]}

SMITH, DW ^{[1
]}

机构：

[1] RECKITT & COLMAN LTD,DIV SERV,HULL HU8 7DS,N HUMBERSHIRE,ENGLAND

来源：

BRITISH MEDICAL JOURNAL | 1979年 / 2卷 / 6183期

关键词：

D O I：

10.1136/bmj.2.6183.163

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The analgesic agent Temgesic (buprenorphine) was made available under monitored release regulations for one year, which yielded data from 1736 doctors on 9123 patients. An analysis of 17 120 administrations of the drug confirmed the results of the pre-licensing clinical studies encompassing data from nine British hospitals on 483 patients. No important new adverse effects attributable to the product were observed, and apart from giving reassurance, the usefulness of monitored release is questioned in the light of the relatively small amount of additional information arising from it. © 1979, British Medical Journal Publishing Group. All rights reserved.

引用

页码：163 / 165

页数：3